🇺🇸 FDA
Pipeline program

Axatilimab (INCA034176)

INCA034176-256

Phase 2 small_molecule active

Quick answer

Axatilimab (INCA034176) for Chronic Graft-Versus-Host Disease is a Phase 2 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Incyte Biosciences Distribution B.V.
Indication
Chronic Graft-Versus-Host Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials